Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design The agency accepts the invitation

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”

As he addressed FDA employees, HHS Secretary Robert F. Kennedy Jr. described the Trump era as a “generational opportunity to make the regulatory agency live up to its foundational ideals” and emerge from the morass of what he described as the “deep state.”

Gene-based blood test for melanoma may detect early signs of cancer return

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.

April 18, 2025

Vol.51 No.15

Drugs & Targets

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA on April 11 approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.

April 18, 2025

Vol.51 No.15

Drugs & Targets

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

FDA announced on April 10 its efforts to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.

April 18, 2025

Vol.51 No.15

Cancer Policy

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

A federal judge ruled that the FDA lacks the statutory authority to regulate laboratory developed tests, finding squarely in favor of plaintiffs in the consolidated lawsuits brought by American Clinical Laboratories Association, Association for Molecular Pathology, and others. ASCP submitted an amicus brief supporting the plaintiffs.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

April 11, 2025

Vol.51 No.14

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design

The agency accepts the invitation

YOU MAY BE INTERESTED IN

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”

Gene-based blood test for melanoma may detect early signs of cancer return

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

Renew today!

Subscriber content

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design

The agency accepts the invitation

YOU MAY BE INTERESTED IN

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”Whistleblowers will be “honored”

Gene-based blood test for melanoma may detect early signs of cancer return

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”